Safety Assessment of Intravenous Application of the Homeopathic Medicine Viscum Album D3 in Dogs

A. Valle, L. R. Aguiar, H. Brunel, P. Malard, R. Andrade
{"title":"Safety Assessment of Intravenous Application of the Homeopathic Medicine Viscum Album D3 in Dogs","authors":"A. Valle, L. R. Aguiar, H. Brunel, P. Malard, R. Andrade","doi":"10.53043/2347-3894.acam90014","DOIUrl":null,"url":null,"abstract":"Background: Viscum album (VA) extracts have a wide variety of biologically active compounds that can be used in the treatment of various diseases, with cancer being the main one. However, few data on the effects of homeopathic VA are found in the literature, even though commercially VA formulations are available, with extremely low doses of its active compounds. Previous studies used the anthroposophical form of Viscum and provided information on the mechanisms of action of this drug in tumor cells or in cells of the immune system. Materials and methods: This study aimed to evaluate the safety of intravenous and subcutaneous application of D3 homeopathic Viscum album (VAD3) in dogs. Healthy dogs (n=7) underwent blood collection for blood cells count and biochemistry analysis and clinical examinations 7 days prior and at days 0, 3, 5, 7, 10, 12, and 14 after the beginning of treatment. The dogs received intravenous application of VAD3 at days 0, 5, 10, and 14, and subcutaneous at days 3, 7, and 12. Results: There was a transient increase in the number of monocytes (P=0.0022) at day 5, while there were no significant (P>0.05) changes in any of the other blood endpoints over time. Nevertheless, all blood parameters remained within the reference values for the species. All animals completed the study in good health conditions. According to the Quality-of-Life Assessment Questionnaire, all animals showed improvement in mood and appetite after receiving VAD3. Conclusion: The homeopathic medicine VAD3 is safe for intravenous and subcutaneous applications in dogs, besides possibly bringing benefits to the entire organism.","PeriodicalId":72312,"journal":{"name":"Asian journal of complementary and alternative medicine : A-CAM","volume":" ","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2021-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Asian journal of complementary and alternative medicine : A-CAM","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.53043/2347-3894.acam90014","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Background: Viscum album (VA) extracts have a wide variety of biologically active compounds that can be used in the treatment of various diseases, with cancer being the main one. However, few data on the effects of homeopathic VA are found in the literature, even though commercially VA formulations are available, with extremely low doses of its active compounds. Previous studies used the anthroposophical form of Viscum and provided information on the mechanisms of action of this drug in tumor cells or in cells of the immune system. Materials and methods: This study aimed to evaluate the safety of intravenous and subcutaneous application of D3 homeopathic Viscum album (VAD3) in dogs. Healthy dogs (n=7) underwent blood collection for blood cells count and biochemistry analysis and clinical examinations 7 days prior and at days 0, 3, 5, 7, 10, 12, and 14 after the beginning of treatment. The dogs received intravenous application of VAD3 at days 0, 5, 10, and 14, and subcutaneous at days 3, 7, and 12. Results: There was a transient increase in the number of monocytes (P=0.0022) at day 5, while there were no significant (P>0.05) changes in any of the other blood endpoints over time. Nevertheless, all blood parameters remained within the reference values for the species. All animals completed the study in good health conditions. According to the Quality-of-Life Assessment Questionnaire, all animals showed improvement in mood and appetite after receiving VAD3. Conclusion: The homeopathic medicine VAD3 is safe for intravenous and subcutaneous applications in dogs, besides possibly bringing benefits to the entire organism.
查看原文
分享 分享
微信好友 朋友圈 QQ好友 复制链接
本刊更多论文
顺势疗法药物Viscum Album D3在犬体内静脉应用的安全性评价
背景:Viscum album (VA)提取物具有多种生物活性化合物,可用于治疗多种疾病,以癌症为主要治疗对象。然而,在文献中很少发现顺势疗法VA的效果数据,即使商业VA配方可用,其活性化合物的剂量极低。先前的研究使用了人智学形式的Viscum,并提供了该药物在肿瘤细胞或免疫系统细胞中的作用机制的信息。材料与方法:本研究旨在评价D3顺势疗法Viscum album (VAD3)在犬体内静脉和皮下应用的安全性。健康犬(n=7)在治疗前7天和治疗开始后第0、3、5、7、10、12和14天采血进行血细胞计数、生化分析和临床检查。在第0、5、10和14天静脉注射VAD3,在第3、7和12天皮下注射。结果:第5天单核细胞数量短暂增加(P=0.0022),而其他任何血液终点随着时间的推移均无显著变化(P < 0.05)。尽管如此,所有血液参数仍在参考值范围内。所有动物在良好的健康状况下完成了研究。根据生活质量评估问卷,所有动物在接受VAD3后情绪和食欲都有所改善。结论:顺势疗法药物VAD3在犬体内静脉和皮下应用是安全的,并可能对整个机体产生益处。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 去求助
来源期刊
自引率
0.00%
发文量
0
期刊最新文献
SFI Reduces the Nucleocytoplasmic Transportation of HMGB1 by Upregulating HDAC3 in LPS-induced RAW264.7 Cells Magnesium – The Metabolic Blockbuster The Controversy: Whether Sucralose Could Increase Blood Glucose in The Body? Rare Clinical Conditions Caused by Dry Eye Bioinformatics-based Prediction of Character of Envelope Glycoprotein and Analysis of Epitopes of B- and T-cell of gp120
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
已复制链接
已复制链接
快去分享给好友吧!
我知道了
×
扫码分享
扫码分享
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1